Sab biotherapeutics provides company update for q1 2023 financial results

Sioux falls, s.d., may 16, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), (sab), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (higg), also known as fully-human polyclonal antibodies, without the need for human donors, yesterday reported financial results for the first quarter ended march 31, 2023, and provided a company update.
SABS Ratings Summary
SABS Quant Ranking